PHOTOCURE ASA
Sector unknown·PHO · Oslo Børs·Fiscal year to 31/12/2024
Exposure profile
Derived from what the company itself writes. Empty directions mean the report doesn't mention themes of that type.
In their own words
Grouped by theme, from the management review in the annual report. A · The company itself is a verbatim quote, B · From the report is without a verified quote.
Europe
Geography
StrategyPositive impact: strengthens
“Photocure’s primary markets for growth, given the Company’s two direct sales organizations and a majority of the market still to be penetrated by Hexvix/ Cysview with BLC. Photocure regained the sales and marketing rights to Hexvix in continental Europe in the fourth quarter of 2020 and regained the rights to Cysview in Canada in January 2022. As a result, the Company remains positioned to take advantage of the growth opportunities in these regions.”
Annual report 2024A · The company itself
Geography
“Photocure is commercializing Hexvix/ Cysview directly in the U.S., Canada, and Europe, and has strategic partnerships with Genotests SpA in Chile, Asieris in China, Endotherapeutics in Australia/ New Zealand, Equity Pharma in South Africa, and IGL Medical in Israel.”
Annual report 2024A · The company itself
Geography
“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”
Annual report 2024A · The company itself
Geography
“Photocure operates globally with headquarters in Oslo, Norway, and additional offices in Princeton, USA, and Düsseldorf, Germany. We also maintain affiliates in France and Canada.”
Annual report 2024A · The company itself
United States
Geography
StrategyPositive impact: strengthens
“Photocure’s primary markets for growth, given the Company’s two direct sales organizations and a majority of the market still to be penetrated by Hexvix/ Cysview with BLC. Photocure regained the sales and marketing rights to Hexvix in continental Europe in the fourth quarter of 2020 and regained the rights to Cysview in Canada in January 2022. As a result, the Company remains positioned to take advantage of the growth opportunities in these regions.”
Annual report 2024A · The company itself
Geography
“Photocure is commercializing Hexvix/ Cysview directly in the U.S., Canada, and Europe, and has strategic partnerships with Genotests SpA in Chile, Asieris in China, Endotherapeutics in Australia/ New Zealand, Equity Pharma in South Africa, and IGL Medical in Israel.”
Annual report 2024A · The company itself
Geography
“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”
Annual report 2024A · The company itself
Geography
“Photocure operates globally with headquarters in Oslo, Norway, and additional offices in Princeton, USA, and Düsseldorf, Germany. We also maintain affiliates in France and Canada.”
Annual report 2024A · The company itself
Chains in: USD vs DKK/EUR mixed effect
Healthcare and hospitals
End markets
Market
“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”
Annual report 2024A · The company itself
Market
“Photocure’s customers consist of urologists, hospitals, clinics and the bladder cancer patients they treat. Customers are directly affected by the quality and safety of Photocure products.”
Annual report 2024A · The company itself
Market
“Transport | Storage | Distribution to Hospitals, Wholesalers, Pharmacies purchase the product Marketing Authorization Holder Product Quality & Safety Surveillance Sales & Marketing Customer Support & Training Ensures Access to the product & BLC procedure Supports further Research & Clinical Trials in Bladder Cancer End users Bladder Cancer Patients get staged | diagnosed | follow up procedures Urology Healthcare Professionals conduct the BLC procedure with the Product Medical Equipment for Blue Light Cystoscopy is provided by 3rd Party Medical Device companies, depending on Market Authorizations Value chain oversight 4.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens, GLP-1 and obesity treatment mixed effect
Labour and wages
Raw materials and inputs
DriverNegative impact: weakens
“Hospitals and other medical institutions may restrict access for our staff which will make the sales and support activities more challenging and therefore may have a negative impact on Photocure’s results and cash flows. Hospitals and other medical institutions may find limited availability of nursing and other staff.”
Annual report 2024A · The company itself
DriverPositive impact: strengthens
“At the end of 2024, the organization comprised of 101 employees, all but two of whom were full-time employees.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“We are proud to actively work on our compensation philosophy to offer fair, attractive, equitable pay based on experience, knowledge, and position responsibilities. We consider both internal pay guidelines and external market competitive financials when developing our remuneration package, independent of age, gender, origin, nationality, or any other.”
Annual report 2024A · The company itself
Medical devices
Technology
InputNegative impact: weakens
“Use of Hexvix/Cysview requires installation of Blue Light Cystoscopes which are manufactured and sold by other companies, only one of which is approved with Cysview in the U.S. These companies’ ability and willingness to develop and promote these products may affect Photocure’s results and cash flows.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“New clinical research and real world data provide the scientific community with new insights to improve bladder cancer care. In 2024, we have engaged in 15 research projects, underscoring our commitment and tangible contribution to the lives of bladder cancer patients through our support of the scientific advancement of care in this domain.”
Annual report 2024A · The company itself
Market
“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”
Annual report 2024A · The company itself
Chains in: Ageing population strengthens
Nordics
Geography
StrategyPositive impact: strengthens
“Photocure’s primary markets for growth, given the Company’s two direct sales organizations and a majority of the market still to be penetrated by Hexvix/ Cysview with BLC. Photocure regained the sales and marketing rights to Hexvix in continental Europe in the fourth quarter of 2020 and regained the rights to Cysview in Canada in January 2022. As a result, the Company remains positioned to take advantage of the growth opportunities in these regions.”
Annual report 2024A · The company itself
Geography
“Photocure is commercializing Hexvix/ Cysview directly in the U.S., Canada, and Europe, and has strategic partnerships with Genotests SpA in Chile, Asieris in China, Endotherapeutics in Australia/ New Zealand, Equity Pharma in South Africa, and IGL Medical in Israel.”
Annual report 2024A · The company itself
Geography
“Photocure’s product Hexvix ® /Cysview ® is available in over 30 countries, with its established specialist commercial and medical teams in North America and Europe.”
Annual report 2024A · The company itself
Cybersecurity (products and services)
Technology
DriverNegative impact: weakens
“Data protection & IT security As a company in the pharmaceutical sector working with research and development and cooperating with physicians and patient advocacy groups, Photocure and/or its research partners may need to gather and store personal data as part of its research and development practices or business operations. In addition, as a listed company on the Oslo Stock Exchange, information security and data protection are also an important part of the company’s obligations to its shareholders and the marketplace.”
Annual report 2024A · The company itself
StrategyPositive impact: strengthens
“Photocure’s security platform is audited annually according to ISEA3402 and ISAE3000 by PWC. The ISAE reports are also mapped up to the Cloud Control Matrix framework to fit industry standards defined by the Cloud Security Alliance.”
Annual report 2024A · The company itself
Chains in: Cyber attacks and IT security risk strengthens
Chains out: this strengthens Digitalisation
Artificial intelligence
Technology
StrategyPositive impact: strengthens
“Moving forward, Photocure expects that the Precision Medicine / Precision Diagnostics movement will grow more important. We anticipate that the application of precision uro-oncology will continue to be implemented at all stages of bladder cancer, starting with the research stage, with the aim of customizing cancer treatment. Blue light cystoscopy with Hexvix/Cysview will likely be key in identifying certain types of patients in order to tailor their cancer treatment.”
Annual report 2024A · The company itself
Chains out: this strengthens Data centres, strengthens Semiconductors and electronic components, strengthens Semiconductor industry
Hybrid work and office use
Macro
StrategyPositive impact: strengthens
“As our culture is built on trust, Photocure offers hybrid remote work arrangements across its locations in Norway, Germany and the U.S. for its non-customer facing employees, which represents approximately 40% of its global team.”
Annual report 2024A · The company itself
Chains out: this weakens Office and commercial property
Rare diseases and orphan drugs
End markets
Market
“At Photocure, we focus all our efforts and resources on delivering transformative solutions to improve the lives of bladder cancer patients. Our medicinal product makes cancer cells visible for physicians so they can optimize the diagnoses, staging and treatments for cancer patients.”
Annual report 2024A · The company itself
Retail
End markets
Market
“Transport | Storage | Distribution to Hospitals, Wholesalers, Pharmacies purchase the product Marketing Authorization Holder Product Quality & Safety Surveillance Sales & Marketing Customer Support & Training Ensures Access to the product & BLC procedure Supports further Research & Clinical Trials in Bladder Cancer End users Bladder Cancer Patients get staged | diagnosed | follow up procedures Urology Healthcare Professionals conduct the BLC procedure with the Product Medical Equipment for Blue Light Cystoscopy is provided by 3rd Party Medical Device companies, depending on Market Authorizations Value chain oversight 4.”
Annual report 2024A · The company itself
Chains in: Consumer spending strengthens
Currency exposure
Macro
DriverNegative impact: weakens
“The increase in operating expenses is mainly driven by foreign exchange effects, merit and inflation.”
Annual report 2024A · The company itself
DriverNegative impact: weakens
“The net financial losses were driven mainly by the Ipsen earnout payments and foreign exchange losses and were partially offset by interest income and foreign exchange gains.”
Annual report 2024A · The company itself
Inflation
Macro
DriverNegative impact: weakens
“Inflationary pressures in the economy and budget tightening may inhibit the hospitals’ ability to invest in equipment. This may have a negative impact on the Company’s revenues, results and cash flows.”
Annual report 2024A · The company itself
DriverNegative impact: weakens
“The increase in operating expenses is mainly driven by foreign exchange effects, merit and inflation.”
Annual report 2024A · The company itself
Chains out: this weakens Consumer spending, strengthens Interest rates
Contract manufacturers as a business (EMS, CMO, CRO)
End markets
InputNegative impact: weakens
“As a business with outsourced manufacturing and logistics, Photocure relies on suppliers, individuals or organizations who provide goods and services to the company. Photocure is thereby directly and indirectly exposed to risks and opportunities in its business relations and supply chain.”
Annual report 2024A · The company itself
Chains in: Biotech and drug development strengthens
Asia and emerging markets
Geography
InputNegative impact: weakens
“One of the other medium risk suppliers is in Israel. This subcontractor is owned by a major and renowned international company. In this region, water scarcity is a concern, and Israel’s control over water resources and access to water in Palestinian territories, whether for the population or production, poses known human rights risk.”
Annual report 2024A · The company itself
Geography
“Photocure is commercializing Hexvix/ Cysview directly in the U.S., Canada, and Europe, and has strategic partnerships with Genotests SpA in Chile, Asieris in China, Endotherapeutics in Australia/ New Zealand, Equity Pharma in South Africa, and IGL Medical in Israel.”
Annual report 2024A · The company itself
Labour regulation
Regulation
DriverNegative impact: weakens
“These processes ensure a nondiscriminating, secure working environment, follow local labor law regulations and are compliant with the Norwegian Working Environment Act, the European Directive 89/381- OSH and the U.S. employment law and standards, as well as aligning to industry best practices.”
Annual report 2024A · The company itself
DriverPositive impact: strengthens
“According to the Global Rights Index provided by Transparency International and the International Trade Union Confederation (ITUC), the countries where we operate are categorized as having low to moderate risks of workers’ rights violations.”
Annual report 2024A · The company itself
AI regulation
Regulation
DriverNegative impact: weakens
“The privacy laws in the U.S. are being implemented at a state level effective from 2023 and continuing through 2026. The California Privacy Rights Act (CPRA) is modelled after GDPR.”
Annual report 2024A · The company itself
Denmark
Geography
Geography
“Photocure operates globally with headquarters in Oslo, Norway, and additional offices in Princeton, USA, and Düsseldorf, Germany. We also maintain affiliates in France and Canada.”
Annual report 2024A · The company itself
Competitors mentioned in the report
No named competitors in the report.
Financial figures
| Revenue latest fiscal year | 0.53 bn NOK |
| Revenue growth vs. the year before, same method | 4.9 % |
| EBITDA reported by the company | 0.05 bn NOK |
| Net debt debt incl. leasing minus cash | N/A |
| Diluted EPS per share | -0.12 NOK |
Source: annual report (ESEF) A. See the report
Criteria
| Profit | ✗ |
| Growing | ✓ |
| Healthy balance sheet | N/A |
Only the criteria that can be computed from financial statements on this page. The remaining criteria (such as price and dividend) need a share price and are in the analysis.
Figures are in the report's currency (NOK), not converted to DKK. Quotes are shown as the company's own words in the report's original language.